HIV/AIDS Treatment and Prevention in the Modern Era

Mudge Elizabeth^*
*Correspondence: Mudge Elizabeth, Department of Medicine & Advanced Technology, Arizona State University, Phoenix, Arizona, USA, Email:

Keywords

HIV • AIDS • Immune system

Introduction

ART regimens have evolved over the years, becoming more effective, convenient and tolerable. Modern ART options include single-tablet regimens, reducing the pill burden for patients. Additionally, long-acting injectable ART is in development, offering an alternative to daily oral medication. The primary goal of ART is to achieve and maintain viral load suppression, which means that the level of HIV in the bloodstream becomes undetectable. When viral load is undetectable, the risk of transmitting the virus to sexual partners is greatly reduced. This concept is known as Undetectable = Untransmittable (U=U). Pre-Exposure Prophylaxis (PrEP) is a powerful prevention tool for individuals at high risk of HIV infection [1]. It involves taking a daily pill to reduce the risk of contracting HIV. PrEP has proven highly effective when used consistently. Post-Exposure Prophylaxis (PEP) is a short-term treatment taken after potential exposure to HIV, such as through unprotected sex or sharing needles. PEP can significantly reduce the risk of infection if started within 72 hours of exposure.

Key populations, including men who have sex with men, sex workers, people who inject drugs and transgender individuals, often face elevated risks of HIV transmission. Tailored prevention strategies, including education, access to PrEP and PEP and harm reduction programs, is crucial for addressing these disparities. Combination prevention approaches involve using a combination of strategies, including ART, PrEP, condoms, regular testing and harm reduction, to maximize HIV prevention efforts [2]. These multifaceted approaches are particularly effective in diverse populations. Stigma remains a significant barrier to HIV/AIDS prevention and treatment. Raising awareness, promoting inclusivity and reducing stigma are vital components of modern prevention and treatment efforts. Educating communities and healthcare providers is essential for dispelling myths and reducing discrimination.

Literature Review

Early diagnosis of HIV is critical for initiating timely treatment and preventing further transmission. Efforts to increase HIV testing, particularly in high-risk populations and promote routine testing as part of regular healthcare are essential components of modern prevention. The Joint United Nations Programme on HIV/AIDS has set ambitious targets known as the 90-90-90 goals. By 2020, the aim was for 90% of people living with HIV to be aware of their status, 90% of those diagnosed to be on ART and 90% of those on treatment to achieve viral suppression [3]. These targets reflect a concerted global effort to control the HIV/ AIDS pandemic. Despite remarkable progress, challenges remain. Access to HIV prevention and treatment services varies worldwide and disparities persist among different populations. Adherence to ART, the emergence of drug resistance and the need for lifelong treatment are ongoing concerns. The landscape of HIV/AIDS treatment and prevention has evolved dramatically in the modern era.

ART has transformed HIV/AIDS into a manageable condition and PrEP and PEP offer powerful prevention tools. Combination prevention approaches, stigma reduction and global initiatives like the 90-90-90 targets provide a roadmap for controlling the pandemic. While HIV/AIDS continues to pose challenges, advances in science, medicine and public health have brought us closer than ever to the goal of ending the epidemic. Continued efforts in research, education and global cooperation are crucial for achieving this milestone and ensuring a world free of HIV/AIDS [4]. This 1500-word article provides an overview of the current state of HIV treatment and prevention in the modern era, emphasizing advances in ART, prevention strategies like PrEP and PEP, combination approaches, stigma reduction and global initiatives. It also acknowledges challenges and underscores the importance of continued efforts to control and ultimately end the HIV/AIDS pandemic. Ongoing research is essential to advance our understanding of HIV/ AIDS and improve treatment and prevention strategies.

Discussion

Innovations in drug development, including novel antiretroviral drugs with fewer side effects and improved effectiveness, hold promise for the future. Additionally, efforts to develop an effective HIV vaccine continue, with researchers exploring various approaches to elicit protective immune responses. Community engagement remains a cornerstone of successful HIV/ AIDS prevention and treatment efforts. Empowering individuals to take charge of their sexual health, seek testing and care and access support services is crucial. Peer-led initiatives, support groups and community-based organizations play pivotal roles in reducing stigma and ensuring that people living with HIV have the resources they need. Young people are a key demographic in the fight against HIV/AIDS [5]. Comprehensive sex education, youth-friendly healthcare services and targeted prevention campaigns are essential to equip young individuals with the knowledge and tools to protect themselves from HIV. Addressing gender disparities is integral to HIV prevention and treatment. Women and girls often face unique vulnerabilities, including higher rates of infection and limited access to resources. Promoting gender equity, addressing gender-based violence and ensuring access to sexual and reproductive health services are essential components of the modern HIV response.

HIV/AIDS is a global challenge that requires global solidarity. International partnerships, funding mechanisms such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and collaboration among countries, organizations and communities are vital for a coordinated response. The vision of an AIDSfree generation remains within reach. Achieving this goal will require sustained commitment to HIV/AIDS prevention, testing and treatment [6]. While significant progress has been made, ending the epidemic will necessitate addressing social determinants of health, expanding access to care and redoubling efforts to reach marginalized populations.

Conclusion

HIV treatment and prevention in the modern era represent a testament to the power of science, medicine and collective action. Advances in ART, innovative prevention strategies and global initiatives have transformed the trajectory of the pandemic. However, the journey is far from over and ongoing commitment, research and collaboration are essential to the ultimate goal of ending HIV/AIDS once and for all. In the remarkable progress in HIV/AIDS treatment and prevention underscores the resilience and determination of individuals, communities and the global healthcare community. With continued efforts, we can look forward to a future where HIV/AIDS is a thing of the past and the world is free from the burden of this devastating disease. This conclusion encapsulates the importance of research, community engagement, gender equity, global solidarity and the pursuit of an AIDS-free generation. It emphasizes the need for sustained commitment and collaboration to ultimately overcome the HIV/AIDS pandemic and highlights the progress made thus far.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Foka, Frank Eric Tatsing, Nanabi Manamela, Steven Maluta Mufamadi and Hazel Tumelo Mufhandu. "Potential of Azadirachta indica as a capping agent for antiviral nanoparticles against SARS-COV-2." BioMed Res Int (2022).

Google Scholar, Crossref, Indexed at

2. Fauci, Anthony S. "HIV and AIDS: 20 years of science." Nat Med 9 (2003): 839-843.

Google Scholar, Crossref, Indexed at

3. Diphoko, Thabo, Simani Gaseitsiwe, Ishmael Kasvosve and Sikhulile Moyo, et al. "Prevalence of rilpivirine and etravirine resistance mutations in HIV-1 subtype C-infected patients failing nevirapine or efavirenz-based combination antiretroviral therapy in Botswana." AIDS Res Hum Retrovir 34 (2018): 667-671.

Google Scholar, Crossref, Indexed at

4. Quashie, Peter K., Thibault Mesplède and Mark A. Wainberg. "HIV drug resistance and the advent of integrase inhibitors." Curr Infect Dis Rep 15 (2013): 85-100.

Google Scholar, Crossref, Indexed at

5. Malet, Isabelle, Olivier Delelis, Marc-Antoine Valantin and Brigitte Montes, et al. "Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro." Antimicrob Agents Chemother 52 (2008): 1351-1358.

Google Scholar, Crossref, Indexed at

6. Drain, Paul K., Ashley R. Bardon, Jane M. Simoni and Tim R. Cressey, et al. "Point-of-care and near real-time testing for antiretroviral adherence monitoring to HIV treatment and prevention." Curr HIV/AIDS Rep 17 (2020): 487-498.

Google Scholar, Crossref, Indexed at